Courey seemed quite concerned about the Generic business when they were trying to acquire King a while back I thought they may seek to diversify outside or perhaps get into Bio-generics.
Dew from your posts you seem to follow the generic business quite a bit. Thoughts on Courey aside are you familiar with the Merck KG Generic business, do you think it is a good deal for MYL or just "empire building" at the expense of diluting shareholders? TIA
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.